Home » Authors » Kim Coghill

Articles by Kim Coghill

CuraGen, Seattle Genetics Form Cancer Deal Worth Up To $32M

June 23, 2004

Momenta's Stock Closes Up After IPO Brings In $34.7M

June 23, 2004

CuraGen, Seattle Genetics Form Cancer Deal Worth Up To $32M

June 23, 2004

Momenta's Stock Closes Up After IPO Brings In $34.7M

June 23, 2004

As BioShield Signing Nears, BioShield II Planning Begins

June 22, 2004

As BioShield Signing Nears, BioShield II Planning Begins

June 22, 2004

After Reagan's Death, Pressure Mounts For Human ESC Reform

June 21, 2004

After Reagan's Death, Pressure Mounts For Human ESC Reform

June 21, 2004

Santarus Gets FDA Approval For Rapinex Powder Version

June 17, 2004

Axonyx Begins Second Pivotal Phenserine Trial In Alzheimer's

June 17, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.